Medpace (NASDAQ:MEDP) Stock Acquired Rep. David Taylor

Representative David Taylor (Republican-Ohio) recently bought shares of Medpace Holdings, Inc. (NASDAQ:MEDP). In a filing disclosed on March 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in Medpace stock on February 26th. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) – DAVE” account.

Representative David Taylor also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 2/26/2026.
• Sold $1,001 – $15,000 in shares of Fifth Third Bancorp (NASDAQ:FITB) on 2/26/2026.
• Sold $1,001 – $15,000 in shares of Parker-Hannifin (NYSE:PH) on 2/26/2026.
• Sold $1,001 – $15,000 in shares of International Business Machines (NYSE:IBM) on 2/26/2026.
• Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 2/26/2026.
• Sold $1,001 – $15,000 in shares of Marathon Petroleum (NYSE:MPC) on 2/26/2026.
• Sold $1,001 – $15,000 in shares of Lam Research (NASDAQ:LRCX) on 2/26/2026.
• Sold $1,001 – $15,000 in shares of Kroger (NYSE:KR) on 2/26/2026.
• Sold $15,001 – $50,000 in shares of International Business Machines (NYSE:IBM) on 2/26/2026.
• Sold $15,001 – $50,000 in shares of Salesforce (NYSE:CRM) on 2/26/2026.

Medpace Stock Performance

NASDAQ MEDP opened at $478.54 on Tuesday. The company has a market capitalization of $13.58 billion, a PE ratio of 31.28, a price-to-earnings-growth ratio of 2.26 and a beta of 1.44. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $628.92. The company has a 50-day simple moving average of $532.11 and a 200 day simple moving average of $539.65.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. The firm had revenue of $708.45 million during the quarter, compared to the consensus estimate of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The company’s revenue was up 32.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Institutional Trading of Medpace

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Quent Capital LLC purchased a new stake in shares of Medpace in the third quarter worth $25,000. Optiver Holding B.V. bought a new position in Medpace in the 3rd quarter worth about $27,000. Geneos Wealth Management Inc. raised its holdings in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares in the last quarter. Steigerwald Gordon & Koch Inc. purchased a new stake in shares of Medpace in the 4th quarter valued at about $30,000. Finally, Elyxium Wealth LLC bought a new stake in shares of Medpace during the 4th quarter valued at about $30,000. Institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on MEDP shares. Barclays raised Medpace from an “underweight” rating to an “equal weight” rating and set a $500.00 price objective for the company in a report on Friday. BMO Capital Markets reiterated a “market perform” rating on shares of Medpace in a research report on Wednesday, February 11th. TD Cowen upgraded shares of Medpace from a “sell” rating to a “hold” rating and reduced their target price for the stock from $462.00 to $419.00 in a research note on Wednesday, February 18th. Mizuho set a $582.00 price target on shares of Medpace in a research note on Wednesday, February 11th. Finally, Royal Bank Of Canada assumed coverage on shares of Medpace in a report on Tuesday, March 3rd. They issued an “outperform” rating and a $522.00 price objective for the company. Five analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Medpace has an average rating of “Hold” and an average target price of $486.67.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.